remdesivir in COVID-19 severe or critically - Summary of results Outcome TE 95% CI n k I2 ROB Pub. bias deathsdetailed results CAP-China (Wang et al.), 2020 1.10 [0.49; 2.45]
1.10 [0.49 ; 2.45 ] CAP-China (Wang et al.), 2020 1 0% 236 NA not evaluable clinical deteriorationdetailed results CAP-China (Wang et al.), 2020 0.95 [0.55; 1.64]
0.95 [0.55 ; 1.64 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvementdetailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
1.23 [0.87 ; 1.74 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable clinical improvement (14-day)detailed results CAP-China (Wang et al.), 2020 1.21 [0.64; 2.28]
1.21 [0.64 ; 2.28 ] CAP-China (Wang et al.), 2020 1 0% 236 NA not evaluable clinical improvement (28-day)detailed results CAP-China (Wang et al.), 2020 1.37 [0.79; 2.39]
1.37 [0.79 ; 2.39 ] CAP-China (Wang et al.), 2020 1 0% 236 NA not evaluable clinical improvement (7-day)detailed results CAP-China (Wang et al.), 2020 0.99 [0.18; 5.51]
0.99 [0.18 ; 5.51 ] CAP-China (Wang et al.), 2020 1 0% 236 NA not evaluable clinical improvement (time to event analysis only)detailed results CAP-China (Wang et al.), 2020 1.23 [0.87; 1.74]
1.23 [0.87 ; 1.74 ] CAP-China (Wang et al.), 2020 1 0% 237 NA not evaluable AE leading to drug discontinuationdetailed results CAP-China (Wang et al.), 2020 2.43 [0.79; 7.45]
2.43 [0.79 ; 7.45 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable serious adverse eventsdetailed results CAP-China (Wang et al.), 2020 0.64 [0.33; 1.23]
0.64 [0.33 ; 1.23 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable deep vein thrombosisdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable elevated liver enzymesdetailed results CAP-China (Wang et al.), 2020 0.36 [0.13; 1.01]
0.36 [0.13 ; 1.01 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable hyperbilirubinemiadetailed results CAP-China (Wang et al.), 2020 1.09 [0.42; 2.79]
1.09 [0.42 ; 2.79 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable pulmonary embolismdetailed results CAP-China (Wang et al.), 2020 0.50 [0.03; 8.10]
0.50 [0.03 ; 8.10 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable renal impairmentdetailed results CAP-China (Wang et al.), 2020 1.01 [0.03; 30.33]
1.01 [0.03 ; 30.33 ] CAP-China (Wang et al.), 2020 1 0% 233 NA not evaluable 0.2 5.0 1.0 relative treatment effect www.metaEvidence.org 2024-11-01 00:19 +01:00
TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers);
k: number of studies; n: total number of patients;
ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1;
studied treatment is better when TE < 1;
pathologies: 91
- treatments: 510
- roots T: 290